CHEK1 and endometrial cancer: In summary, CHK1 inhibitors have shown preliminary antitumor activity in multiple studies, and their combination with other treatments can accelerate tumor cells’ elimination, which also displays some activity in endometrial cancer cell lines, but more evidence is needed to support it due to a lack of relevant clinical studies.